Drug intelligence / Profile preview

n-phenyl pyrazoline-2

Development stage
Preclinical
Lead developer
Universitas Gadjah Mada
Modality
Small Molecules
Administration
Not Established
01

Overview

**N-phenyl pyrazoline-2** is a *synthetic small molecule* from the pyrazoline derivative family, specifically a 2-pyrazoline substituted with a phenyl group at the nitrogen. It has been experimentally investigated for its *anticancer activity*, particularly against cervical cancer (HeLa) cells. The most studied variant, often called "pyrazoline 2" or "P2," and closely related derivatives exhibit cytotoxic activity, strongly inhibiting cell proliferation, colony formation, migration, and cancer stem cell-like properties via inhibition of the epidermal growth factor receptor (EGFR) pathway. Molecular docking and in vitro studies support that N-phenyl pyrazoline-2 targets EGFR, suppressing cell viability and migration, suggesting potential as a lead compound for anticancer drug development, notably for solid tumors such as cervical, breast, and colorectal cancer[1][3].

Other names
N-phenylpyrazoline-2N-phenylpyrazoline2N-phenylpyrazoline 2
02

Targets

EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR2 (Vascular endothelial growth factor receptor 2)PRKCZ (Protein kinase C zeta)FAK (Focal adhesion kinase)

Beyond the preview

Go deeper on n-phenyl pyrazoline-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-phenyl pyrazoline-2.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call